ערך בספרים למניה: Absci Corporation (ABSI)

Absci relies on venture capital flows and the investment readiness of biotech partners, while remaining immune to seasonal fluctuations. The company's growth is based on the precision of AI algorithms in protein design and the volume of deals with pharma behemoths, with the metric standing at 1.43. This price chart on the GURU.Markets platform confirms its status as a leader in antibody generation, backed by high industry confidence.

The integration of generative AI into protein synthesis allows Absci (ABSI) to radically optimize R&D costs by capitalizing on technological advantages. This efficiency is reflected in the calculation of the difference between total assets and liabilities divided by the number of shares, which demonstrates the real value of an investor's stake through the dynamics of equity per share.